Human Vaccines & Immunotherapeutics · 2021 · 24 citations · 25 references
MedicineImmunologyOncologyCancer ImmunologyImmunotherapyVaccinologyCancer ImmunotherapyCancer VaccinesCervical CancerHuman Papillomavirus InfectionVaccine-based ImmunotherapyVector-based VaccinesAdjuvant Antigen PresentationAntigen Presenting CellsAntigen-adjuvant InteractionsCellular ImmunotherapyImmune Response To HpvTherapeutic Hpv VaccinesTherapeutic Human Papillomavirus Vaccines
-based vectors infect antigen-presenting cells (APC) and secrete HPV-LLO fusion proteins within the APC cytoplasm, these proteins are processed and presented to cytotoxic T lymphocytes (CTL), thus generating a new population of CTLs specific to HPV antigens. These HPV-specific CTLs destroy HPV infected cells. ADXS11-001 has demonstrated safety results in phase I-II studies in women with cervical cancer and is being assessed in clinical trials in patients with HPV-positive anal canal and head and neck cancers.
25
Global burden of cancers attributable to infections in 2012: a synthetic analysis
Martyn Plummer, Catherine de Martel, Jérôme Vignat et al. · The Lancet Global Health · 2016 · 1.6K citations · Full text
Cornelia L. Trimble, Matthew P. Morrow, Kimberly A. Kraynyak et al. · The Lancet · 2015 · 714 citations
Medicine, Immunology, Oncology +17
Susanne K. Kjær, Kristján Sigurðsson, Ole‐Erik Iversen et al. · Cancer Prevention Research · 2009 · 328 citations · Full text